Vanda Pharmaceuticals (VNDA) Tops Q3 EPS by 9c
Tweet
Share
E-mailGet Alerts VNDA Hot Sheet
Price: $5.43 +1.69%
Revenue Growth %: +24.1%
Financial Fact:
Intangible asset amortization: 2.94M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +24.1%
Financial Fact:
Intangible asset amortization: 2.94M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q3 EPS of ($0.11), $0.09 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $28.3 million versus the consensus estimate of $28.84 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Geberit AG (GEBN:SW) (GBERY) PT Raised to CHF712 at Jefferies
- RBC Capital Reiterates Outperform Rating on Aviva PLC (AV:LN) (AVVIY)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
